← Back to Search

Cleaning and Disinfecting Solution

BL-3100-NBR03 for Refractive Errors

Q: What is the upper limit for participants of this research project?

<p>The sponsor of this trial, Bausch &#x26; Lomb Incorporated, requires the enrollment of 340 eligible participants from various sites including Lee &#x26; Woo Optometry in San Francisco and Chester T Roe III MD Prof LLC in Denver.</p>

N/A

Waitlist Available

Research Sponsored by Bausch & Lomb Incorporated

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

Study Summary

This trial will study the safety and effectiveness of contact lenses worn for 3 months, with scheduled replacement visits. 340 people will participate in 22 sites in the US.

Eligible Conditions

Refractive Errors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall comfort averaged over all scheduled follow-up visits

Dental Deposits

The proportion of eyes with any slit-lamp findings greater than Grade 2 over all follow-up visits.

+1 more

Side effects data

From 2014 Phase 4 trial • 40 Patients • NCT01602692

40%

Nausea

10%

Vomiting

100%

80%

60%

40%

20%

Study treatment Arm

Tumescent Solution With Dilute Epinephrine

Tumescent Solution With Dilute Lidocaine and Epinephrine

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: BL-3100-NBR03Experimental Treatment1 Intervention

BL-3100-NBR03 multi-purpose solution

Group II: renu® Advanced FormulaActive Control1 Intervention

renu® Advanced Formula multi-purpose solution

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

BL-3100-NBR03 multi-purpose solution

2023

N/A

~300

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Bausch & Lomb IncorporatedLead Sponsor

251 Previous Clinical Trials

57,123 Total Patients Enrolled

6 Trials studying Refractive Errors

603 Patients Enrolled for Refractive Errors

Daniel DonatelloStudy DirectorBausch & Lomb Incorporated

4 Previous Clinical Trials

1,674 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there multiple sites operating this investigation within the US?

"Currently, this medical trial is welcoming participants at 14 different sites. These locations include San Francisco, Denver and Jacksonville as well as a myriad of other cities. To avoid excessive travel requirements, it's best to select the location closest to you if participating in the study."

Answered by AI

What is the upper limit for participants of this research project?

"The sponsor of this trial, Bausch & Lomb Incorporated, requires the enrollment of 340 eligible participants from various sites including Lee & Woo Optometry in San Francisco and Chester T Roe III MD Prof LLC in Denver."

Answered by AI

Is this research endeavor still open to enrollees?

"Affirmative. Clinicaltrials.gov lists this medical trial as actively recruiting participants, having been posted on April 12th 2023 and updated most recently on June 9th 2023. To date, 340 prospective applicants are needed across 14 distinct centres."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and Disinfecting Solution

2023. "A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and Disinfecting Solution". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05565937.